Compassionate Use

Early Access Program: Access to innovative medicines for patients

A pharmaceutical company with a focus on clinical research implemented a compassionate use program at the request of the medical profession. We drew up the necessary contracts for this, tailored to the specific requirements of the intended treatment and the needs of the doctors involved. As a result, patients were able to benefit from a new treatment option at an early stage.

Experimental therapy

Swiss doctors enquired with an international pharmaceutical company about the availability of a medicinal product not approved in Switzerland for the treatment of a fatal disease. This was intended for the treatment of a small number of patients for whom the available standard therapy was not suitable or all treatment options had been exhausted. We advised the company to enable availability in these cases.